308 related articles for article (PubMed ID: 22955108)
1. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
2. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
[TBL] [Abstract][Full Text] [Related]
4. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
[TBL] [Abstract][Full Text] [Related]
5. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
[TBL] [Abstract][Full Text] [Related]
7. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
8. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of endometrial carcinoma.
Matias-Guiu X; Prat J
Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
[TBL] [Abstract][Full Text] [Related]
10. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.
Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP
Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210
[TBL] [Abstract][Full Text] [Related]
12. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
14. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas.
Djordjevic B; Barkoh BA; Luthra R; Broaddus RR
Mod Pathol; 2013 Oct; 26(10):1401-12. PubMed ID: 23599155
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
16. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG).
Mackay HJ; Gallinger S; Tsao MS; McLachlin CM; Tu D; Keiser K; Eisenhauer EA; Oza AM
Eur J Cancer; 2010 May; 46(8):1365-73. PubMed ID: 20304627
[TBL] [Abstract][Full Text] [Related]
18. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.
Oliva E; Sarrió D; Brachtel EF; Sánchez-Estévez C; Soslow RA; Moreno-Bueno G; Palacios J
J Pathol; 2006 Apr; 208(5):708-13. PubMed ID: 16429393
[TBL] [Abstract][Full Text] [Related]
19. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.
Turbiner J; Moreno-Bueno G; Dahiya S; Sánchez-Estevez C; Hardisson D; Prat J; Oliva E; Palacios J
Mod Pathol; 2008 Aug; 21(8):925-36. PubMed ID: 18500270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]